FDA spells out how the Covid-19 vari­ants im­pact the ef­fec­tive­ness of Re­gen­eron, Eli Lil­ly mAb treat­ments

The FDA on Thurs­day af­ter­noon up­dat­ed its three fact sheets on the mon­o­clon­al an­ti­body treat­ments from Eli Lil­ly and Re­gen­eron, of­fer­ing new da­ta on the sus­cep­ti­bil­i­ty of the SARS-CoV-2 vari­ants orig­i­nat­ing in the UK, Brazil, South Africa, Cal­i­for­nia and New York to each of the mAb ther­a­pies.

“Some vari­ants can cause re­sis­tance to one or more of the mAb ther­a­pies au­tho­rized to treat COVID-19,” FDA said. “Health care providers should re­view the au­tho­rized fact sheets for in­for­ma­tion on the use of the au­tho­rized mAb ther­a­pies against cur­rent­ly cir­cu­lat­ing vi­ral vari­ants.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.